Key facts
- This page summarizes Douglas Holtzman's Form 4 filing for Icosavax, Inc..
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Jul 2023, 19:43.
Douglas Holtzman - 03 Jul 2023 Form 4 Insider Report for Icosavax, Inc.
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- N/A
- Reported as of
- 03 Jul 2023
- Net transaction value
- -$127,733
- SEC form
- 4
- Accepted by SEC
- 03 Jul 2023, 19:43:15 UTC
- Prior SEC filing
- 05 Apr 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elizabeth Bekiroglu, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Douglas Holtzman filed Form 4 for Icosavax, Inc. on 03 Jul 2023.
Change
- Previous filing in this sequence was filed on 05 Apr 2023.
- Current net transaction value: -$127,733.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ICVX
transaction
Common Stock
Options Exercise
- Transaction value
- $17,010
- Shares
- +16,356
- Change %
- +5.6%
- Price
- $1.04*
- Shares after
- 306,410
- Date
- 03 Jul 2023
- Ownership
- Direct
ICVX
transaction
Common Stock
Sale
- Transaction value
- $124,660
- Shares
- -14,261
- Change %
- -4.7%
- Price
- $8.74
- Shares after
- 292,149
- Date
- 03 Jul 2023
- Ownership
- Direct
- Footnotes
- F1, F2
ICVX
transaction
Common Stock
Sale
- Transaction value
- $20,083
- Shares
- -2,095
- Change %
- -0.72%
- Price
- $9.59
- Shares after
- 290,054
- Date
- 03 Jul 2023
- Ownership
- Direct
- Footnotes
- F1, F3
ICVX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,792
- Date
- 03 Jul 2023
- Ownership
- By Stanley Holtzman(
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ICVX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -16,356
- Change %
- -36%
- Price
- $0.000000
- Shares after
- 28,621
- Date
- 03 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,443
- Exercise price
- $1.04
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 5 footnotes
Footnote F1
The sales reported herein were made pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on December 2, 2022.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.38 to $9.28. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.38 to $9.88. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
Douglas Holtzman, Ph.D. holds power-of-attorney (POA) over the shares owned by Stanley Holtzman. As POA, Dr. Holtzman holds voting and dispositive control over such shares. Dr. Holtzman disclaims beneficial ownership of the shares over which he has POA except to the extent of any pecuniary interest therein.
Footnote F5
25% of the shares subject to the option vested on 1/14/2022, and 1/48th of the shares subject to the option vest monthly thereafter.